Patent · US Active

Use of stathmin as a biomarker of drug response to furazanobenzimidazoles

US9366682B2 · kind B2 · utility

1Cited by

2References

97Claims

0Family size

Assignee

Basilea Pharmaceutica AG · CH

Inventors

Heidi Lane · Biel-Benken, CH
Felix Bachmann · Basel, CH

Key dates

Filing date	Jan 19, 2012
Grant date	Jun 14, 2016
Priority date	—
Expiry date	Jan 19, 2032

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldMeasurement
WIPO sectorInstruments

Abstract

Use of stathmin as a biomarker for predicting the response, such as resistance, to a compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.